StreetInsider.com News Articles

Form S-8 MiNK Therapeutics, Inc.

Thu, 13 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260813/26921925.html

Form S-8 MiNK Therapeutics, Inc.

Thu, 13 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260813/26921925.html

Form 10-Q MiNK Therapeutics, Inc. For: Jun 30

Thu, 13 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260813/26921861.html

Form 10-Q MiNK Therapeutics, Inc. For: Jun 30

Thu, 13 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260813/26921861.html

Form 8-K MiNK Therapeutics, Inc. For: Aug 13

Thu, 13 Aug 2026 07:41:00 -0400

si-local-file:///var/storage/secattach/20260813/26916563.html

Form 8-K MiNK Therapeutics, Inc. For: Aug 13

Thu, 13 Aug 2026 07:41:00 -0400

si-local-file:///var/storage/secattach/20260813/26916563.html

MiNK Therapeutics reports Q2 2026 results and Phase 2 trial data

Thu, 13 Aug 2026 07:30:17 -0400

MiNK Therapeutics (NASDAQ: INKT) reported a net loss of $3.1 million, or $0.62 per share, for the second quarter ended June 30, 2026, down from a net loss of $4.2 million, or $1.06 per share, in the same period a year earlier, according to a company press release.

Cash and cash equivalents stood at $8.8 million as of June 30, 2026, compared with $13.4 million at December 31, 2025. Cash used in operations was $2.1 million for the quarter, up from $1.6 million in the second quarter of 2025.

The company also reported early observations from its randomized Phase 2 trial of

MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury

Thu, 13 Aug 2026 07:30:00 -0400

First patients treated in randomized Phase 2 trial C-1300-02 were alive at Day 28, with improved oxygenation, resolution of ARDS with return to spontaneous breathing and liberation from vasopressor support
Clinical recovery and biologic readouts moved in the same direction; serum and bronchoalveolar lavage analyses showed reduced inflammatory markers and biologic changes associated with immune recovery and tissue repair; no major serious adverse events were attributed to agenT-797
Launched international paid named-patient access program established for physicians to request access to agenT-797, subject to per-patient regulatory authorization; building cross-border infrastructure and access

NEW YORK, Aug.

MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury

Thu, 13 Aug 2026 07:30:00 -0400

First patients treated in randomized Phase 2 trial C-1300-02 were alive at Day 28, with improved oxygenation, resolution of ARDS with return to spontaneous breathing and liberation from vasopressor support
Clinical recovery and biologic readouts moved in the same direction; serum and bronchoalveolar lavage analyses showed reduced inflammatory markers and biologic changes associated with immune recovery and tissue repair; no major serious adverse events were attributed to agenT-797
Launched international paid named-patient access program established for physicians to request access to agenT-797, subject to per-patient regulatory authorization; building cross-border infrastructure and access

NEW YORK, Aug.

MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates

Thu, 06 Aug 2026 08:19:00 -0400

NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that it will report financial results for the second quarter ended June 30, 2026, before the market opens on Thursday, August 13, 2026.

The Company will host a conference call and webcast at 8:30 AM ET that morning to review financial results and provide a corporate update focused on the clinical advancement of agenT-797, MiNK’s off-the-shelf allogeneic iNKT cell

MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates

Thu, 06 Aug 2026 08:19:00 -0400

MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates

Thu, 06 Aug 2026 08:19:00 -0400

MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates

Thu, 06 Aug 2026 08:19:00 -0400

Agenus posts Q2 revenue of $34.5M, plans Phase 3 colon cancer trial